EMEA-002783-PIP01-20 - paediatric investigation plan

neratinib
PIPHuman

Key facts

Invented name
Nerlynx
Active Substance
neratinib
Therapeutic area
Oncology
Decision number
P/0246/2020
PIP number
EMEA-002783-PIP01-20
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Treatment of breast cancer
Route(s) of administration
Oral use
Contact for public enquiries

Pierre Fabre Médicament

E-mail: medical_information@pierre-fabre.com
Tel. +33 800326326

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

Share this page